Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection

Glycoconjugate Journal

Volumn 30, Issue 9, 2013, Pages 843-855

  Cox, Andrew D ^a   St Michael, Frank ^a   Aubry, Annie ^a   Cairns, Chantelle M ^a   Strong, Philippa C R ^a   Hayes, Alexander C ^a   Logan, Susan M ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Clostridium difficile; Conjugate vaccine; Lipoteichoic acid

Indexed keywords

BACTERIAL VACCINE; CARRIER PROTEIN; EXOTOXIN; GLYCOCONJUGATE; LIPOTEICHOIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONJUGATION; CONTROLLED STUDY; CROSS REACTION; DEACYLATION; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; VACCINE PRODUCTION;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; MUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; IMMUNIZATION; LIPOPOLYSACCHARIDES; MICE; RABBITS; TEICHOIC ACIDS; VACCINES, CONJUGATE;

EID: 84887990533     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-013-9489-3     Document Type: Article

References (29)

1. Shah, D., Dang, M.-D., Hasbun, R., Koo, H.L., Jiang, Z.-D., DuPont, H.L., Garey, K.W.: Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Exp. Rev. Anti-Infect. Ther. 8, 555-564 (2010)
2. Khanna, S., Pardi, D.S., Aronson, S.L., Kammer, P.P., Orenstein, R., St. Sauver, J.L., et al.: The epidemiology of community acquired Clostridium difficile infection: a population based study. Am. J. Gastroenterol. 107, 89-95 (2012)
3. Lucado, J., Gould, C., Elixhauser, A.: Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP Statistical Brief #124. January 2012. Agency for Healthcare Research and Quality, Rockville, MD
4. Gerding, D.N., Muto, C.A., Owens Jr., R.C.: Measures to control and prevent Clostridium difficile infections. Clin. Infect. Dis. 46, S43-S49 (2008)
5. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., et al.: Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl. J. Med. 362, 197-205 (2010)
6. Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J.G., Ng, K.K.-S., MacKenzie, R., et al.: Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286, 8961-8976 (2011)
7. Kelly, C.P., Kyne, L.: The host immune response to Clostridium difficile. J. Med. Microbiol. 60, 1070-1079 (2011)
8. Tian, J.-H., Fuhrmann, S.R., Kluepfel-Stahl, S., Carman, R.J., Ellingsworth, L., Flyer, D.C.: A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30, 4249-4258 (2012)
9. Mascio, C.T.M., Mortin, L.I., Howland, K.T., van Praagh, A.D.G., Zhang, S., Arya, A. et al.: In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.: Antimicrob. Ag. Chemother. 56, 5023-5030 (2012).
10. Villano, S.A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E., Gerding, D.N.: Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M#, in healthy subjects. Antimicrob. Ag. Chemother. 56, 5224-5229 (2012)
11. Lawrence, B., Reddy, S.S.: Fecal microbiota transplantation for recurrent Clostridium difficile infection. J. Clin. Gastro. 45, S159-S167 (2011)
12. Otczyk, D.C., Cripps, A.W.: Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenza type b and pneumococcal vaccines. Pneumonia 2, 2-18 (2013)
13. Gasparini, R., Panatto, D.: Meningococcal glycoconjugate vaccines. Human Vacc. 7, 170-182 (2011)
14. Poxton, I.R., Ivor Cartmill, T.D.: Immunochemistry of the cell-surface carbohydrate antigens of Clostridium difficile. J. Gen. Microbiol. 128, 1365-1370 (1982)
15. Poxton, I.R. & Byrne, M.D.: Immunological analysis of the EDTA-soluble antigens of Clostridium difficile and related species. J. Gen. Microbiol. 122, 41-46.
16. Ganeshapillai, J., Vinogradov, E., Rousseau, J., Weese, J.S., Monteiro, M.A.: Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohydr. Res. 343, 703-710 (2008)
17. Monteiro, M.A., Ma, Z., Bertolo, L., Jiao, Y., Arroyo, L., Hodgins, D., et al.: Carbohydrate-based Clostridium difficile vaccines. Exp. Rev. Vacc. 12, 421-431 (2013)
18. Danieli, E., Lay, L., Proietti, P., Berti, F., Costantino, P., Adamo, R.: First synthesis of C. difficile PS-II cell wall polysaccharide repeating unit. Org. Letts. 13, 378-381 (2011).
19. Adamo, R., Romano, M.R., Berti, F., Leuzzi, R., Tontini, M., Danieli, E.: Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PS-II cell wall polysaccharide. CS Chem. Biol. 7, 1420-1428 (2012)
20. Oberli, M.A., Hecht, M.-L., Bindschlader, P., Adibekian, A., Adam, T., Seeberger, P.H.: A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem. Biol. 18, 580-588 (2011)
21. Martin, C.E., Broecker, F., Oberli, M.A., Komor, J., Mattner, J., Anish, C., Seeberger, P.H.: Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope. J. Am. Chem. Soc. 135, 9713-9722 (2013)
22. Reid, C.W., Vinogradov, E., Li, J., Jarrell, H.C., Logan, S.M., Brisson, J.-R.: Structural characterization of surface glycans from Clostridium difficile. Carbohydr. Res. 354, 65-73 (2012)
23. Martin, C. E., Broecker, F., Eller, S., Oberli, M. A., Anish, C., Pereira, C.L., and Seeberger, P. H. Glycan arrays containing Clostridium difficile lipoteichoic acid oligomers as tools towards a carbohydrate vaccine. Chem. Comm (Camb.) doi: 10.1039/c3cc43545h (2013).
24. Chaudhary, V.K., Jinno, Y., Fitzgerald, D., Pastan, I.: Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. PNAS USA 87, 308-312 (1990)
25. Sawardeker, D.G., Sloneker, J.H., Jeanes, A.: Quantitative determination of monosaccharides as their alditol acetates by gas liquid chromatography. Anal. Chem. 37, 1602-1604 (1965)
26. Cox, A.D., Li, J., Brisson, J.-R., Moxon, E.R., Richards, J.C.: Structural analysis of the lipopolysaccharide from Neisseria meningitidis strain BZ157 galE: localisation of two phosphoethanolamine residues in the inner core oligosaccharide. Carbohydr. Res. 337, 1435-1444 (2002)
27. Cox, A.D., St. Michael, F., Neelamegan, D., Lacelle, S., Cairns, C.M., Giuliani, M.M., et al.: Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading. Glycoconjugate J. 27, 643-648 (2010)
28. Cox, A.D., St. Michael, F., Cairns, C.M., Lacelle, S., Filion, A., Neelamegan, D., Wenzel, C.Q., Richards, J.C.: Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera. Glycoconjugate J. 28, 165-182 (2011)
29. St. Michael, F., Cairns, C., Filion, A.L., Neelamegan, D., Lacelle, S., Cox, A.D.: Investigating the candidacy of lipopolysaccharide-based glycoconjugates as vaccines to combat Mannheimia haemolytica. 28, 165-182 (2011).